Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against KaloBios Pharmaceuticals, Inc. (“KaloBios” or the “Company”) (Nasdaq: KBIO). Investors who purchased or otherwise acquired shares between November 19, 2015 and December 17, 2015, inclusive (the “Class Period”) are encouraged to contact the Firm prior to the February 16, 2016, lead plaintiff motion deadline.

If you purchased shares of KaloBios during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the complaint, the Company issued materially false and misleading statements to investors and/or failed to disclose that: (1) the CEO of KaloBios was engaged in a scheme involving the illegal use of stock from Retrophin, Inc. to pay off debts associated with other unrelated business ventures; and (2) the discovery and revelation of that scheme would likely undermine KaloBios’ operations and prospects.

If you purchased shares of KaloBios during the Class Period, you have until February 16, 2016 to ask the Court to appoint you as lead plaintiff. If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

KHANG & KHANG LLPJoon M. Khang, Esq.Telephone: 949-419-3834Facsimile: 949-225-4474joon@khanglaw.com

Humanigen (CE) (USOTC:HGEN)
Graphique Historique de l'Action
De Juil 2024 à Juil 2024 Plus de graphiques de la Bourse Humanigen (CE)
Humanigen (CE) (USOTC:HGEN)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024 Plus de graphiques de la Bourse Humanigen (CE)